SCHEMBL7185780

SCHEMBL7185780

CC(C)(C)[Si](C)(C)OCc1ccc2ccc(C=O)cc2c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.46
BACE1 P56817 1/20 0.36
ALDH1A1 P00352 6/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
HCAR2 Q8TDS4 1/20 0.34
CYP2A6 P11509 3/20 0.33
MAOA P21397 2/20 0.33
MAOB P27338 2/20 0.33
TACR2 P21452 1/20 0.33
NPC1 O15118 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
AOX1 Q06278 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
USP14 P54578 1/20 0.32
TSHR P16473 1/20 0.32
FDPS P14324 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1206221 0.96 RAB9A (0.47) RAB9ABACE1ALDH1A1MEN1MAPT
SCHEMBL979052 0.84 BACE1 (0.40) RAB9ABACE1ALDH1A1MEN1MAPT
SCHEMBL4332449 0.81 MAOA (0.47) RAB9ABACE1ALDH1A1MAOAMAOB
SCHEMBL7174917 0.80 CA2 (0.37) RAB9ABACE1NPC1USP14
SCHEMBL1204975 0.78 RAB9A (0.34) RAB9ABACE1MAPTMAOANPC1
SCHEMBL3139624 0.77 RAB9A (0.54) RAB9AALDH1A1MEN1MAPTKMT2A
SCHEMBL5881932 0.77 BACE1 (0.35) BACE1
Alcohol SCHEMBL9337072 0.77 MAOA (0.43) RAB9ABACE1ALDH1A1MAOAMAOB
SCHEMBL1206536 0.76 BACE1 (0.45) BACE1ALDH1A1MEN1MAPTKMT2A
SCHEMBL3139506 0.75 CA12 (0.54) RAB9AALDH1A1CYP2A6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0944590-B1 AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS DIMENSIONAL PHARM INC (US) 2002-03-20 EP claimed
EP-1268495-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA INC. (CA) 2003-01-02 EP disclosed
US-6465444-B2 PROTEIN TYROSINE PHOSPHATASES(PTP-1B); ANTIDIABETIC, ANTITUMOR AND ANOREXIGENIC AGENTS; COMBINATION THERAPY MERCK FROSST CANADA & CO. 2002-10-15 US disclosed
US-20020002149-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-01-03 US disclosed
WO-2001070754-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002149-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO RAB9A 911/4885BACE1 2985/4885ALDH1A1 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.